Supernus Pharmaceuticals (SUPN) Change in Accured Expenses (2011 - 2026)

Supernus Pharmaceuticals (SUPN) has 16 years of Change in Accured Expenses data on file, last reported at $28.6 million in Q1 2026.

• On a quarterly basis, Change in Accured Expenses rose 1904.41% year-over-year to $28.6 million in Q1 2026; TTM through Mar 2026 was $2.6 million, a 111.14% increase from a year earlier, with the FY2025 full-year figure at -$24.6 million, down 63.61% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at $28.6 million, up from -$40.3 million in the prior quarter.
• Over the last five years, Change in Accured Expenses for SUPN reached as high as $41.2 million in Q2 2022 and fell as low as -$47.1 million in Q4 2023.
• Historically, Change in Accured Expenses has averaged -$1.7 million across 5 years, with a median of $1.4 million in 2025.
• Across the five-year window, Change in Accured Expenses tumbled 9545.93% in 2025 and surged 1904.41% in 2026, its largest moves.
• Year by year, Change in Accured Expenses stood at -$6.8 million in 2022, then plunged by 592.06% to -$47.1 million in 2023, then surged by 99.11% to -$418000.0 in 2024, then tumbled by 9545.93% to -$40.3 million in 2025, then soared by 170.99% to $28.6 million in 2026.
• Per Business Quant data, the three most recent Change in Accured Expenses figures were $28.6 million in Q1 2026, -$40.3 million in Q4 2025, and $3.5 million in Q3 2025.